Company intelligence / Profile preview

HemoGenix

Colorado Springs, Colorado, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

HemoGenix provides in vitro toxicity testing services and has developed proprietary platforms for assessing drug safety. The company's HALO®-Tox HT platform incorporates Suspension Expansion Culture™ (SEC™) Technology and ATP bioluminescence technology, achieving over 80% concordance between in vitro and in vivo results.

Industry: Drug Discovery Services

Partnerships

Works with small and medium-sized biopharmaceutical companiesmore than half of the top 50 biopharmaceutical companies

Beyond the preview

Go deeper on HemoGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HemoGenix.

Explore the full profile